CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
“We are excited to advance our partnership with Labcorp, continuing to provide increased access to oncology care for patients leveraging Labcorp’s extensive footprint and oncology experience,” Margot Schoenborn, CEO of OmniSeq, said in a press statement. “We are making this test available globally to biopharmaceutical customers for incorporation into their clinical trials for biomarker stratification, and to support new precision medicine oncology approaches to drug and companion diagnostic development.”
OmniSeq Insight is available to U.S.-based clinicians through Labcorp and in Canada through Dynacare, a Labcorp company. The test is also available to global biopharmaceutical companies through Labcorp Drug Development.
Pages: 1 2